Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | MMP13 | P45452 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918991 | 0.86 | MAPK14 (0.50) | MAPK14CYP3A4MMP13HTTSMN1; SMN2 | |
| SCHEMBL15377800 | 0.85 | MAPK14 (0.42) | MAPK14CYP3A4MMP13HTTSMN1; SMN2 | |
| SCHEMBL919807 | 0.84 | CYP2C19 (0.47) | MAPK14CYP3A4HTTRAB9AALDH1A1 | |
| SCHEMBL919163 | 0.84 | SCN9A (0.47) | MAPK14CYP3A4MMP13MMP2MMP1 | |
| SCHEMBL919803 | 0.84 | MEN1 (0.43) | HTTSMN1; SMN2LMNARAB9AALDH1A1 | |
| SCHEMBL919293 | 0.81 | SCN9A (0.42) | MAPK14CYP3A4MMP13MMP2MMP1 | |
| SCHEMBL919294 | 0.80 | SLC1A3 (0.44) | MAPK14MMP13MMP2MMP1SCN9A | |
| SCHEMBL919046 | 0.80 | MMP13 (0.49) | MMP13RAB9A | |
| SCHEMBL920087 | 0.79 | ALDH1A1 (0.48) | CYP3A4HTTSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL919061 | 0.78 | SMN1; SMN2 (0.46) | MAPK14HTTSMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | claimed |
| US-20060217403-A1 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY | 2006-09-28 | — | — | US | claimed |
| EP-1032377-A4 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2006-06-14 | — | — | EP | claimed |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2003-07-10 | — | — | US | claimed |
| US-6500825-B2 | SODIUM CHANNEL BLOCKERS USED TO TREAT AMYOTROPHIC LATERAL SCLEROSIS; ANALGESICS, ANTICONVULSANTS, ANTIDEPRESSANTS, LOCAL ANESTHETICS AND ANTIARRHYTHMICS | EURO-CELTIQUE S.A. (LU) | 2002-12-31 | — | — | US | claimed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | claimed |
| EP-1032377-A1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-09-06 | — | — | EP | claimed |
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | disclosed |
| US-8426431-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-7872127-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2201944-A2 | Substituted 2-Aminoacetamides and the Use Thereof | Purdue Neuroscience Company (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-2201945-A2 | Substituted 2-Aminoacetamides and the Use Thereof | Purdue Neuroscience Company (US) | 2010-06-30 | — | — | EP | disclosed |
| US-6500825-B2 | SODIUM CHANNEL BLOCKERS USED TO TREAT AMYOTROPHIC LATERAL SCLEROSIS; ANALGESICS, ANTICONVULSANTS, ANTIDEPRESSANTS, LOCAL ANESTHETICS AND ANTIARRHYTHMICS | EURO-CELTIQUE S.A. (LU) | 2002-12-31 | — | — | US | disclosed |
| US-6479484-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE DISCOVERY THAT THESE COMPOUNDS ACT AS BLOCKERS OF SODIUM CHANNELS; PAIN RELIEVERS, TREATMENT OF ARRYTHMIA, LOCAL ANESTHETICS | EURO-CELTIQUE S.A. (LU) | 2002-11-12 | — | — | US | disclosed |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA LTD. | 2002-03-28 | — | — | US | disclosed |
| WO-2000061188-A9 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-02-14 | — | — | WO | disclosed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | disclosed |
| EP-1169060-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061188-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | MAPK14 2405/4885CYP3A4 772/4885MMP13 2548/4885 |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | MAPK14 4016/4885CYP3A4 1339/4885MMP13 2549/4885 |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, SLC1A1, SCN2A | MAPK14 2070/4885CYP3A4 2066/4885MMP13 968/4885 |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, GAP43, SCN2A | MAPK14 2275/4885CYP3A4 710/4885MMP13 2695/4885 |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | MAPK14 2405/4885CYP3A4 772/4885MMP13 2548/4885 |
| US-20060217403-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, GAP43, SCN2A | MAPK14 2243/4885CYP3A4 784/4885MMP13 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.